Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), has announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a net income of $19.4 million, or $1.23 per share, for the fourth quarter, a significant turnaround from a net loss of $9.6 million, or $1.25 per share, for the same period in 2024. For the full year, Curis reported a net loss of $7.6 million, or $0.58 per share, compared to a net loss of $43.4 million, or $6.88 per share, in 2024. The increase in net income for the fourth quarter was attributed to a non-cash gain of $27.2 million related to the release of liability from the sale of future royalties associated with the sale of assets. Revenue for the fourth quarter was $1.1 million, down from $3.3 million in the same quarter last year, primarily due to the sale of the Erivedge intellectual property. Curis continues to focus on its clinical studies, including the TakeAim Lymphoma study, which aims to support filings for accelerated approval in the U.S. and Europe. The company believes its cash and cash equivalents, along with expected proceeds from financing, will support operations into the second half of 2027. Curis management will host a conference call to discuss these results and provide further insights into the company's strategic outlook.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.